




The relative strengths and weaknesses of Moleculin Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Moleculin Biotech Inc is the variable Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 23% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	26,273
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,815
Liabilities, Non-Current	474
Other Assets	11,672
Other Compr. Net Income	-21
Other Expenses	1,681
Other Liabilities	4,855
Other Net Income	1,416
Other Revenues	0
Property and Equipment	272
Research and Development	19,487
Selling, General and Administrative Expense	10,017

Output Variable	Value in 1000 USD
Assets	38,217
Liabilities	12,144
Expenses	31,185
Revenues	0
Stockholders Equity	26,073
Net Income	-29,769
Comprehensive Net Income	-29,780
BaseVar	41,492
ECR before LimitedLiability	107%
Economic Capital Ratio	236%